Our Story

During his residency at UT Southwestern Medical Center, Dr. Michael Giles spent many hours working at an opioid treatment program (OTP) where he witnessed firsthand the hardships patients had to go through in their recovery process.

Not only that, Dr. Giles observed the pain points and opportunities opioid treatment programs face when looking to expand access to methadone and other life saving medication.

In the months to come, Sonara Health was formed under Dr. Giles’ philosophy that facilitating humanized, compassionate and trustworthy interactions between OTP patients and providers will lead to greater outcomes and have a noticeable positive impact on the opioid epidemic.

Our Team

Crafted with kindness and curiosity

Michael Giles, MD

Justin Geller

Chief Executive Officer

Chief Operating Officer

Phil Beck

VP of Growth

Phoebe Goldenberg

Lead Product Designer

Neal Ehardt

Nicolas Montanaro

Lead Software Engineer

Software Engineer

Deon Washington

Zachary Kletter

Customer Success Manager

Kshitij Verma

Business Operations Manager

Sheeba Ibidunni

Omer Kaplan

Chief Product Officer

VP of Operations

Our Purpose

Sonara exists to remove treatment barriers so that people with opioid dependency can live the life they desire.

Modern Framework

Fewer in-person visits makes treatment more convenient and efficent.

Environment of Trust

When treatment doesn’t interfere with their daily lives, patients are more likely to stay the course.

Better Outcomes

With clearer insights into patients' take-home journeys, clinicians can feel confident in making informed treatment decisions.

Media Room

Learn what people are saying about Sonara and the work we do.

Featured

Sonara Health Partners with University of Arkansas for Medical Sciences to Expand Access to Take-Home Methadone

Sonara Health has announced a new partnership with the University of Arkansas for Medical Sciences to responsibly broaden access to take-home methadone for patients who qualify.

Sonara Health Receives $2.5M Grant from NIDA and Funding Allocation from New Jersey

Sonara Health has received a $2.5M grant from the National Institute on Drug Abuse to fund the second phase of a study on Remote Observed Methadone Evaluation.